Analysis of telisotuzumab-EMRELIS market price and drug purchase reference information in pharmacies in various regions

Telisotuzumab (trade name: EMRELIS) is a new type of targeted monoclonal antibody, mainly used to treat patients with specific types of solid tumors such as MET-positive non-small cell lung cancer (NSCLC). It selectively binds to MET receptors on the surface of tumor cells and inhibits the activation of abnormal signaling pathways, thereby blocking tumor cell proliferation and metastasis, and at the same time enhancing the tumor killing effect through immune-mediated mechanisms. As a precision targeted drug, terituzumab provides a new treatment option for some advanced or drug-resistant patients.

In the domestic market, terituzumab is not yet available on the market, so domestic patients cannot currently purchase or use it directly. Since it has not yet been approved by the Food and Drug Administration and cannot be included in the medical insurance reimbursement system, patients who wish to use the drug can only participate in clinical trials or wait for its official launch. Domestic hospitals and pharmacies are also unable to provide legal procurement channels for this drug, so it is necessary to pay careful attention to official marketing information and clinical guideline updates.

In overseas markets, terituzumab has been launched, and its price is approximately 45,000 RMB per vial. The price reflects the research and development costs and clinical value of its innovative targeted drugs, but the economic burden is relatively high for self-paying patients. Currently, there are no generic drugs of terituzumab globally, so overseas original drugs are the only source available.

In terms of purchasing channels, patients need to obtain drugs through regular hospitals, overseas certified pharmacies or legal import channels to ensure drug quality and safety. During use, the physician's prescription and dosage regimen should be strictly followed, and tumor response and potential adverse reactions, such as liver function abnormalities or changes in hematological indicators, should be monitored regularly. Standardized individualized treatment and scientific management are the keys to ensuring efficacy and safety.

Reference materials:https://www.drugs.com/